

# INDEX

- A**  
Adverse Childhood Experiences Study, 18, 19  
African Americans, 129–130  
Alcohol use, screening for, 98–99  
Alternative medicine, 41  
Analgesics, 95–96, 145–148  
Anger, 51; *see also* Hostility  
    in response to illness, 73–75  
Angry and disruptive patients, 148–151  
Anticholinergic effects of drugs, 97  
Antidepressants, 91, 93; *see also* Selective serotonin reuptake inhibitors  
    classes of, 87–88  
    for major depression, 84–88  
    that are CYP 450 inhibitors, 94–95  
Anxiety, 5, 7, 56, 70–72, 76–77; *see also* Denial of illness  
    caregiver stress, guilt, and, 111–114  
    normative and maladaptive, 52–53  
Anxiety disorders; *see also specific disorders*  
    medications for, 87, 89–93
- B**  
Benefit finding, 12  
Benzodiazepines, 87  
Bone density, depression and, 4–5
- C**  
Caffeine use, screening for, 98–99  
Cancer  
    case material, 58, 70–71, 74, 118–120, 126  
    depression and, 4  
    fear of, 56, 58, 74  
Cardiac catheterization, 39  
Child abuse, 17–19  
Chronic obstructive pulmonary disease (COPD), 132  
Chronic symptoms and limitations, 75–78  
Citalopram, 96–97  
Class  
    and disparities in health care, 16  
    and trust in physician-patient relationship, 130  
Cognitive behavioral therapy (CBT), 160–161  
Communication, patient-physician, 124–129  
Control, 56–57, 149  
Coping and illness, 7–13, 35  
Coronary heart failure (CHF), 110  
Cynicism, 6–7  
Cytochrome P450 (CYP 450), 94–95  
Cytokines, 19–20
- D**  
Denial of illness, 57–60  
Dependency and illness, 60–63  
Depression, 2–5, 7, 36, 55, 141; *see also* Antidepressants  
    chronic illness and, 76–78

- Descartes, René, 33–34  
 Diagnostic process, 49–52  
 Diagnostic tests, 51  
 Discontinuation syndrome (serotonergic agents), 101  
 Doctors: *see* Physicians  
 Drug abuse, 77, 144–148  
 Drug interactions, 94–98  
 Drug use, 98–99  
 Dualism, 33–34
- E**  
 Elderly; *see also* Geriatric patients  
 depression in, 3–4  
 Embarrassment, 49–50  
 Emotional states; *see also* Negative trait affect  
 medical effects of, 7  
 Emptiness, sense of, 55–56  
 Endocrine function, 20  
 Escitalopram, 96  
 Ethnicity: *see* Race and ethnicity
- F**  
 Family interventions, suggestions for, 119–120  
 Family members  
 impact of illness on, 109–111, 120–121  
 caregiver stress, guilt, and anxiety, 111–114  
 problematic social support, 115–117  
 strategies for dealing with, 120–121  
 when patients and families don't communicate, 117–119  
 Fear: *see* Anxiety  
 Fluoxetine, 95–96  
 Fluvoxamine, 96–97
- G**  
 Generalized anxiety disorder (GAD), 90–91  
 Geriatric patients; *see also* Elderly  
 drug interactions and special considerations in, 94–98  
 Guilt, 50, 111–114
- H**  
 Health care  
 cost, 37–38  
 crisis in, 36–38  
 disparities in, 16–17  
 Health insurance, 40  
 Heart disease, 110  
 anxiety and, 5  
 depression and, 3  
 PTSD and, 68  
 History taking, 49–50  
 Hospitalized patients, depression in, 3–4  
 Hostility, 5–7; *see also* Angry and disruptive patients  
 Hypervigilance, 53  
 Hypothalamic-pituitary-adrenal (HPA) axis, 20
- I**  
 Illness; *see also specific topics*  
 adapting to, 47–48; *see also specific topics*  
 adjusting to being a patient, 63–64  
 becoming ill, 48–49  
 resuming life after serious illness, 67–73  
 narcissistic injury of, 53–57  
 Immunity, 19–20, 34  
 personality factors and, 11–12  
 stress and, 14–15  
 Insomnia, 68
- M**  
 Major depressive disorder (MDD), 84  
 diagnostic criteria, 84–85  
 Meaning, sense of, 78  
 Medical errors, 40  
 Medical history taking, 49–50  
 Medication abuse and addiction, 144–148  
 Medicine  
 addressing emotions in the context of modern, 31–32, 43–44  
 “compartmentalization” in, 34–35  
 dissatisfaction with Western, 41  
 history, 33–34, 123  
 science and the culture of, 32–36  
 working in the field of, 36–38  
 Mental health professionals, 154  
 referring to, 157, 170–171  
 difficulties in, 158–161  
 how to refer, 168–170  
 when to refer, 161–164

- Mind-body associations  
 integration of research findings, 19–22  
 possible mechanisms of, 20–22  
 “Mind-body problem,” 33–34  
 Myocardial infarction (MI), 3, 68
- N**  
 Negative trait affect, 11  
 Neuroticism, 11  
 Noncompliance, 138–144; *see also*  
 Treatment adherence
- O**  
 Opioids, 95–96, 145–148  
 Optimism, 11–12  
 Organizations offering services and  
 support groups, 164–167  
 Osteoporosis, depression and, 4–5
- P**  
 Pain, chronic, 77; *see also* Analgesics  
 Panic disorder, 70, 91, 148–149  
 diagnostic criteria, 92  
 Paranoia, 149–150; *see also*  
 Hypervigilance  
 Paroxetine, 96, 101  
 Patient satisfaction, 40–41  
 Patients  
 angry and disruptive, 148–151  
 difficult, 137–138; *see also specific*  
*topics*  
 implications for medical practice,  
 153–154  
 what can be learned from, 153–154  
 empowerment, 41  
 Personality factors, 10–12  
 Physician-patient relationship, 39  
 trust in, 123–124, 133–134  
 and adherence, 131–133  
 and communication, 124–129  
 and ethnicity, 129–131  
 Physicians  
 emotional detachment, 39, 120, 132  
 idealization and devaluation of, 40  
 responsibility, 132–133  
 working in medicine today, 36–38  
 Post-traumatic stress disorder (PTSD),  
 67–71, 73, 91–92  
 diagnostic criteria, 93  
 pharmacological interventions, 92–93  
 Psychiatry, 154, 159–160; *see also* Mental  
 health professionals  
 Psychosomatic medicine, 154  
 Psychosomatic symptoms, 72–73, 151–153  
 Psychotherapy, 154; *see also* Mental health  
 professionals  
 Pulmonary disease; *see also* Respiratory  
 illness  
 chronic obstructive, 132
- R**  
 Race and ethnicity  
 and disparities in health care, 16–17  
 and trust in physician-patient  
 relationship, 129–131  
 Religion, 9–10  
 Respiratory illness; *see also* Pulmonary  
 disease  
 upper, 15  
 Rheumatoid arthritis (RA), 12
- S**  
 Science and the culture of medicine, 32–36  
 Selective serotonin reuptake inhibitors  
 (SSRIs), 85–88, 90–91; *see also*  
 Serotonin agents  
 drug interactions and special  
 considerations in geriatric patients,  
 94–98  
 Serotonin agents, special issues in use of,  
 99–102  
 Serotonin syndrome, 99–100  
 Sertraline, 96–97  
 Shame, 49–50  
 Social class: *see* Class  
 Social support, 8–9; *see also* Dependency  
 and illness; Support groups  
 problematic, 115–117  
 St. John’s wort, 97  
 Stress, 13–16  
 caregiver, 111–114  
 Support groups, 164–167
- T**  
 Technology, relationships, and physician  
 authority, 38–43  
 Transference, 151  
 Trauma; *see also* Post-traumatic stress  
 disorder  
 defined, 68

Treatment adherence, 131–133; *see also*  
Noncompliance  
Type A personality, 5–6

**U**

Upper respiratory illness (URI), 15

**V**

Vulnerability, 73

**Z**

Zuger, Abigail, 36–37